Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2012
|
| gptkbp:ATCCode |
N03AX22
|
| gptkbp:CASNumber |
380917-97-5
|
| gptkbp:chemicalFormula |
C23H15N3O
|
| gptkbp:drugClass |
anticonvulsant
|
| gptkbp:eliminationHalfLife |
105 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:genericName |
gptkb:perampanel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fycompa
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Eisai
|
| gptkbp:mechanismOfAction |
AMPA receptor antagonist
|
| gptkbp:metabolism |
liver (CYP3A4/5)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
95-96%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
aggression gait disturbance irritability somnolence |
| gptkbp:status |
FDA approved
EMA approved |
| gptkbp:usedFor |
epilepsy
partial-onset seizures primary generalized tonic-clonic seizures |
| gptkbp:bfsParent |
gptkb:Eisai_Co.,_Ltd.
gptkb:Eisai |
| gptkbp:bfsLayer |
6
|